Bobak Azamian, M.D., Ph.D., has been the driving force behind Tarsus Pharmaceuticals since its inception. With a strong background in medicine and business, he co-founded the company and became its CEO in 2018. Before this, he led Metavention, Inc., focusing...
Bobak Azamian, M.D., Ph.D., has been the driving force behind Tarsus Pharmaceuticals since its inception. With a strong background in medicine and business, he co-founded the company and became its CEO in 2018. Before this, he led Metavention, Inc., focusing on developing treatments for diabetes and metabolic diseases. He also played a key role in Vibrato Medical, creating wearable devices for vascular conditions. Bobak has a solid academic foundation, holding a Bachelor's in Biophysics from Rice University, a Ph.D. in Chemistry from the University of Oxford, and an M.D. from Harvard Medical School. Under his leadership, Tarsus has made significant strides in the biotechnology industry. He also chairs the board, ensuring that technical innovation aligns with business goals. In 2023, he earned a compensation of $632,700, which is heavily tied to Tarsus’s performance, reflecting a structure aimed at driving success for the company and its shareholders. His insider trading track record showcases confidence in his company, with stock holdings peaking around $51.88 million in early 2021. This suggests a deep commitment to Tarsus and belief in its future.